New recommendations for endoscopic eradication therapy in Barrett’s oesophagus
New guideline on use of endoscopic eradication therapy Barrett’s oesophagus has been published.
A new guideline by the ASGE Standards of Practice Committee offers evidence-based recommendations and clinical guidelines addressing key issues related to Endoscopic Eradication Therapy (EET) in the management of Barrett’s oesophagus (BE)-related lesions.
BE is a condition in which the normal lining of the oesophagus develops abnormal lesions, sometimes due to chronic gastroesophageal reflux disease (GERD). It has been identified as a precursor to oesophageal adenocarcinoma (EAC), a type of cancer that continues to become more common. In 2014, there were approximately 18,170 incident cases of oesophageal cancer in the United States, nearly 60 percent of which were EAC. The outlook for patients with EAC has traditionally been poor.
Endoscopic eradication therapy (EET) has significantly changed the management of patients with BE-related lesions and allows a minimally invasive treatment approach that avoids the illness and deaths associated with the surgical procedure ofo esophagectomy (removal of some or most of the oesophagus). Contemporary EET, supported by published literature, entails endoscopic mucosal resection (EMR) of visible lesions within the Barrett’s segment and ablation (removal) techniques that include radiofrequency ablation (RFA) and cryotherapy. Studies show that EET can result in complete removal of diseased tissue, leading to disease remission. This procedure is being performed not only at academic and tertiary care centers, but also among community practices.
This document addresses EET vs. surveillance as optimal management strategy for patients with dysplasia (abnormal growth of cells or tissue) and intramucosal EAC; comparison of EET with oesophagectomy; the role of EMR and ablation; and recommendations for surveillance after achieving complete removal of lesions.
American Society for Gastrointestinal Endoscopy